European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder

European Neuropsychopharmacology

Volumn 23, Issue 10, 2013, Pages 1208-1218

  Coghill, David ^a   Banaschewski, Tobias ^b   Lecendreux, Michel ^c   Soutullo, Cesar ^d   Johnson, Mats ^e   Zuddas, Alessandro ^f   Anderson, Colleen ^g   Civil, Richard ^g   Higgins, Nicholas ^g   Lyne, Andrew ^h   Squires, Liza ^g  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^f UNIVERSITY OF CAGLIARI   (Italy)

^g SHIRE   (United States)

^h Shire Pharmaceuticals   (United Kingdom)

Author keywords

Adolescent; Attention deficit disorder with hyperactivity; Central nervous system stimulants; Child; Lisdexamfetamine dimesylate; Prodrugs

Indexed keywords

AMPHETAMINE DERIVATIVE; DEXAMPHETAMINE; DRUG METABOLITE; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; PRODRUG; PSYCHOSTIMULANT AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADVERSE OUTCOME; ANGINA PECTORIS; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CHILD; CHILD PSYCHIATRY; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG OVERDOSE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV-TR; ELECTROCARDIOGRAM; EUROPE; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERACTIVITY; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPTIMAL DRUG DOSE; OSMOTIC RELEASE ORAL SYSTEM; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAL SIGN; VOMITING;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; LISDEXAMFETAMINE DIMESYLATE; PRODRUGS;

ADOLESCENT; ADOLESCENT BEHAVIOR; APPETITE REGULATION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD BEHAVIOR; DEXTROAMPHETAMINE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMPULSIVE BEHAVIOR; MALE; METHYLPHENIDATE; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 84884288612     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.11.012     Document Type: Article

References (23)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) 2000, American Psychiatric Association, Washington DC.
2. Adler L.A., Goodman D.W., Kollins S.H., Weisler R.H., Krishnan S., Zhang Y., Biederman J. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 2008, 69:1364-1373.
3. American Academy of Pediatrics ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Process of care supplemental appendix. Pediatrics 2011, 128:SI1-SI21. 〈http://pediatrics.aappublications.org/content/suppl/2011/10/11/peds.2011-2654.DC1/zpe611117822p.pdf〉 (accessed 22.05.12).
4. American Academy of Pediatrics ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011, 128:1007-1022.
5. Banaschewski T., Coghill D., Santosh P., Zuddas A., Asherson P., Buitelaar J., Danckaerts M., Dopfner M., Faraone S.V., Rothenberger A., Sergeant J., Steinhausen H.C., Sonuga-Barke E.J., Taylor E. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur. Child Adolesc. Psychiatry 2006, 15:476-495.
6. Biederman J., Boellner S.W., Childress A., Lopez F.A., Krishnan S., Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol. Psychiatry 2007, 62:970-976.
7. Biederman J., Krishnan S., Zhang Y., McGough J.J., Findling R.L. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin. Ther. 2007, 29:450-463.
8. Boellner S.W., Stark J.G., Krishnan S., Zhang Y. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. Clin. Ther. 2010, 32:252-264.
9. Cohen J. A power primer. Psychol. Bull. 1992, 112:155-159.
10. Faraone S.V. Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. J. Atten. Disord. 2012, 16:128-137.
11. Findling R.L., Childress A.C., Cutler A.J., Gasior M., Hamdani M., Ferreira-Cornwell M.C., Squires L. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 2011, 50:395-405.
12. Findling R.L., Childress A.C., Krishnan S., McGough J.J. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectrums 2008, 13:614-620.
13. Goodman D., Faraone S.V., Adler L.A., Dirks B., Hamdani M., Weisler R. Interpreting ADHD rating scale scores: linking ADHD rating scale scores and CGI levels in randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Primary Psychiatry 2010, 17:44-52.
14. Gordon M., Antshel K., Faraone S., Barkley R., Lewandowski L., Hudziak J.J., Biederman J., Cunningham C. Symptoms versus impairment: the case for respecting DSM-IV's Criterion D. J. Atten. Disord. 2006, 9:465-475.
15. May D.E., Kratochvil C.J. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 2010, 70:15-40.
16. National Institute for Health and Clinical Excellence, 2009. Diagnosis and Management of ADHD in Children, Young People and Adults. National Clinical Practice Guideline Number 72. London, UK. (accessed 26.04.2012). http://www.nice.org.uk/nicemedia/live/12061/42060/42060.pdf.
17. NHS Quality Improvement Scotland, 2008. Attention Deficit and Hyperkinetic Disorders. Services Over Scotland. Report of the Implementation Review Exercise. Edinburgh, UK, p. 11876. (accessed 16.05.2012). http://www.healthcareimprovementscotland.org/default.aspx?
18. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr. Dis. Treat. 2010, 6:317-327.
19. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 2007, 164:942-948.
20. Santosh P.J., Taylor E., Swanson J., Wigal T., Chuang S., Davies M., Greenhill L., Newcorn J., Arnold L.E., Jensen P., Vitiello B., Elliott G., Hinshaw S.P., Hechtman L., Abikoff H., Pelham W.E., Wells K., Posner M. Refining the diagnoses of inattention and overactivity syndromes: a reanalysis of the multimodal treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clin. Neurosci. Res. 2005, 5:307-314.
21. Taylor E., Dopfner M., Sergeant J., Asherson P., Banaschewski T., Buitelaar J., Coghill D., Danckaerts M., Rothenberger A., Sonuga-Barke E., Steinhausen H.C., Zuddas A. European clinical guidelines for hyperkinetic disorder-first upgrade. Eur. Child Adolesc. Psychiatry 2004, 13(Suppl. 1):I7-30.
22. Wigal S.B., Kollins S.H., Childress A.C., Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc. Psychiatry Ment. Health 2009, 3:17.
23. Wigal T., Brams M., Gasior M., Gao J., Squires L., Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav. Brain Funct. 2010, 6:34.